Resonant Therapeutics

Resonant Therapeutics combines a biology-forward three-dimensional with machine learning to rapidly develop, functionally annotate, and promote novel cancer therapeutic candidates. Resonant technology can dramatically expand your drug discovery pipeline by customizing tumor microenvironment models to reflect specific disease states and microenvironment conditions.

The modular IMPaCT platform exploits high-fidelity tumor microenvironment models to discover tumor-selective targets and therapeutics that are missed by traditional approaches. The approach is further enhanced by incorporation of specific microenvironmental components, enabling customized interrogation of specific disease states. Antibody therapeutic candidates are applicable to a wide variety of therapeutics (Ab, bi-specifics, ADCs, CAR-T). Resonant's product is tumor-selective. The microenvironment model induces surface protein expression specific to the tumor-immune interaction. It is also tunable. Specific modifications prioritize immune, cancer stem cell, or other specific cell states. Lastly, the platform is fast and scalable. The IMPaCT platform transforms a 4+ year discovery process into a 12-month cycle spanning model selection to in-hand drug candidates.

2450 Holcombe Blvd
Houston, TX 77021
United States